Oppenheimer's 24th Annual Healthcare Conference Provides Investor Access To
Emerging And Established Companies
NEW YORK, Dec. 13, 2013
NEW YORK, Dec. 13, 2013 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of
Oppenheimer Holdings Inc., is pleased to announce the completion of its 24th
Annual Healthcare Conference, which took place on December 10 – 11, 2013, in
New York. More than 130 public and private companies, representing all
major sectors of the healthcare industry including bio & specialty
pharmaceuticals; biotechnology; medical devices; healthcare facilities; life
science tools and diagnostics; healthcare information technology and
distribution, and healthcare providers and servicers participated in this
two-day program. The conference attracted more than 700 attendees.
The Oppenheimer Healthcare Conference consisted of a mix of formal company
presentations and one-on-one meetings.
The keynote speakerTed Kennedy, Jr., President & Co-Founder, The Marwood
Group, providedinsights into the latest developments in Washington , D.C. and
discussed the regulatory environment as well as theheadwinds and tailwinds
across many sectors of the healthcare industry.
"This is Oppenheimer's 24^th consecutive year of producing this conference,
and it demonstrates our long-standing commitment to the healthcare industry.
We are pleased to be able to continue to offer this conference for investors
to meet with emerging and established healthcare companies as they evaluate
the opportunities in the sector over the next 12-18 months," said Erica
Moffett, Managing Director and Associate Director of Research.
Panels included "How Emerging Biopharma Companies Successfully Execute Their
First Commercial Launch," and "China Healthcare Holds Opportunities for Global
Investors and Healthcare Companies: How to Capture Them?" Other panels looked
at the growing use of big data in healthcare and the evolving healthcare model
which included CEOs of two of the leading hospital systems in the U.S.
discussing the significant payment and care delivery changes ahead.
In the current environment of healthcare reform, increased regulation and
rising costs, the conference offered investors a unique opportunity to meet
with CEOs and CFOs of healthcare companies and learn first hand what issues
and trends will drive the sector in 2014 and beyond in the U.S., Europe and
"The Oppenheimer Healthcare Conference has been an excellent forum to
highlight our plans for launching OTREXUP following the NDA approval in
October," said Paul Wotton, President and CEO of Antares Pharma.
Oppenheimer provides research coverage of more than110 companies in the
healthcare sector and is an active underwriter of healthcare stocks.
Oppenheimer & Co. Inc., a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), provides a full range of wealth
management, securities brokerage and investment banking services to
high-net-worth individuals, families, corporate executives, local governments,
businesses and institutions.
Certain statements in this release may constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks, uncertainties and other factors
that could cause actual results to differ materially, as discussed in the
Company's filings with the Securities and Exchange Commission.
SOURCE Oppenheimer & Co. Inc.
Contact: Stefan Prelog, (212) 931-6139
Press spacebar to pause and continue. Press esc to stop.